YU46665B - Postupak za dobijanje peptida i novi peptidi - Google Patents

Postupak za dobijanje peptida i novi peptidi

Info

Publication number
YU46665B
YU46665B YU191887A YU191887A YU46665B YU 46665 B YU46665 B YU 46665B YU 191887 A YU191887 A YU 191887A YU 191887 A YU191887 A YU 191887A YU 46665 B YU46665 B YU 46665B
Authority
YU
Yugoslavia
Prior art keywords
insulin
amino acid
acid residues
peptides
molecule
Prior art date
Application number
YU191887A
Other languages
English (en)
Other versions
YU191887A (en
Inventor
K.H. Joergensen
Original Assignee
Novo Nordisk A/S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK503386A external-priority patent/DK503386D0/da
Priority claimed from DK356987A external-priority patent/DK356987D0/da
Application filed by Novo Nordisk A/S. filed Critical Novo Nordisk A/S.
Publication of YU191887A publication Critical patent/YU191887A/xx
Publication of YU46665B publication Critical patent/YU46665B/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

POSTUPAK ZA DOBIJANJE PEPTIDA I NOVI PEPTIDI, koji sadrže najmanje 20 insulinskih jedinica po ml, naznačen time, što se insulin odnosno derivat insulina opšte formule: u kojoj su X-ovi ostaci kiseline ljudskog insulina ili iste ili različite supstitucije ostataka amino kiseline, čije niže funkcije daju molekulu isti naboj ili veći negativni naboj na neutralnom pH od ovih iz ljudskog insulina, uz uslov da je najmanje jedan X različit od ostataka amino kiseline ljudskog insulina na odnosnoj poziciji u molekulu insulina, i to kada je X u poziciji A8 onda je His ili Phe, X u poziciji A21 je Aps, X u poziciji B5 je Ala, X u poziciji B9 je Leu, X u poziciji B10 je Asn ili Leu, X u poziciji B12 je Asn ili X u poziciji B 26 je Ala, osim toga, preostali X-evi su različitiod ostataka amino kiseline ljudskog insulina na odnosnoj poziciji u molekulu insulina i uz dodatni uslov da jedan ili više ostataka amino kiseline mogu biti uklonjeni iz N- i/ili C-krajeva terminala A- i/ili B-lanca; rastvara u vodi i disperzira putem ultrasoničnog tretmana, s tim što se uvode joni magnezijuma u koncentraciji magnezijuma od oko 0,005 M do 0,5 M pri čemu se dobijenom rastvoru koji ima pH vrednost od oko 3 do 8,5 počeljno ispod 8, sa mogućim sadržajem taloga insulina ili njegovog derivata produženog dejstva, dodaje fosfolipid u prisustvu stabilizirajućeg agensa. Prijava sadrži još 2 nezavisna i 7 zavisnih patentnih zahteva.
YU191887A 1986-10-20 1987-10-19 Postupak za dobijanje peptida i novi peptidi YU46665B (sh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK503386A DK503386D0 (da) 1986-10-20 1986-10-20 Peptidpraeparater
DK356987A DK356987D0 (sh) 1987-07-10 1987-07-10

Publications (2)

Publication Number Publication Date
YU191887A YU191887A (en) 1989-04-30
YU46665B true YU46665B (sh) 1994-01-20

Family

ID=26067111

Family Applications (1)

Application Number Title Priority Date Filing Date
YU191887A YU46665B (sh) 1986-10-20 1987-10-19 Postupak za dobijanje peptida i novi peptidi

Country Status (18)

Country Link
US (1) US5070186A (sh)
EP (1) EP0265213B1 (sh)
KR (1) KR880004819A (sh)
CN (1) CN87107049A (sh)
AU (1) AU616381B2 (sh)
CA (1) CA1316819C (sh)
DE (1) DE3778287D1 (sh)
ES (1) ES2033871T3 (sh)
FI (1) FI86254C (sh)
GR (1) GR3004912T3 (sh)
HU (1) HU201475B (sh)
IE (1) IE60264B1 (sh)
IL (1) IL84203A (sh)
NO (1) NO170754C (sh)
NZ (1) NZ222214A (sh)
PH (1) PH23446A (sh)
PT (1) PT85949B (sh)
YU (1) YU46665B (sh)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534488A (en) * 1993-08-13 1996-07-09 Eli Lilly And Company Insulin formulation
YU18596A (sh) * 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina
AU1870099A (en) * 1998-01-09 1999-07-26 Novo Nordisk A/S Stabilised insulin compositions
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
RU2318492C2 (ru) * 2001-08-27 2008-03-10 Ново Нордиск А/С Баллончик и система подачи лекарственного препарата, включающая в себя такой баллончик
AU2003300126B2 (en) * 2002-12-31 2010-04-01 Altus Pharmaceuticals Inc. Complexes of protein crystals and ionic polymers
CA2512052C (en) * 2002-12-31 2016-06-21 Altus Pharmaceuticals Inc. Human growth hormone crystals and methods for preparing them
US20090023629A1 (en) * 2005-12-23 2009-01-22 Altus Pharmaceuticals Inc. Compositions comprising polycation-complexed protein crystals and methods of treatment using them
CN101573133B (zh) 2006-07-31 2014-08-27 诺沃-诺迪斯克有限公司 Peg化延长的胰岛素
EP2074141B1 (en) 2006-09-22 2016-08-10 Novo Nordisk A/S Protease resistant insulin analogues
CN101674812B (zh) 2007-04-30 2013-12-11 诺沃-诺迪斯克有限公司 干燥蛋白组合物的方法、干燥的蛋白组合物和包含干燥的蛋白的药物组合物
WO2008132229A2 (en) * 2007-04-30 2008-11-06 Novo Nordisk A/S Highly concentrated insulin solutions and compositions
JP5762001B2 (ja) 2008-03-14 2015-08-12 ノボ・ノルデイスク・エー／エス プロテアーゼ安定化インスリンアナログ
WO2009115469A1 (en) 2008-03-18 2009-09-24 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
RS56632B1 (sr) 2008-10-17 2018-03-30 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
PT3345593T (pt) 2009-11-13 2023-11-27 Sanofi Aventis Deutschland Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
ES2855146T3 (es) 2009-11-13 2021-09-23 Sanofi Aventis Deutschland Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
CN101912600B (zh) * 2010-01-11 2014-01-29 杨国汉 改善胰岛素在溶液中稳定性的方法
US8637458B2 (en) * 2010-05-12 2014-01-28 Biodel Inc. Insulin with a stable basal release profile
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
HUE031181T2 (en) 2010-08-30 2017-06-28 Sanofi Aventis Deutschland Use of AVE0010 for the manufacture of a medicament for the treatment of type 2 diabetes
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CN103917241A (zh) 2011-08-29 2014-07-09 赛诺菲-安万特德国有限公司 用于2型糖尿病患者中的血糖控制的药物组合
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
US9481721B2 (en) 2012-04-11 2016-11-01 Novo Nordisk A/S Insulin formulations
US9381247B2 (en) * 2012-04-16 2016-07-05 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
US9399065B2 (en) 2012-04-16 2016-07-26 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and injection site pain of insulin
MX369511B (es) 2013-04-03 2019-11-11 Sanofi Sa Tratamiento de la diabetes mellitus mediante formulaciones de insulinas de acción prolongada.
HUE036702T2 (hu) 2013-10-07 2018-07-30 Novo Nordisk As Inzulinanalóg új származéka
JP6970615B2 (ja) 2014-12-12 2021-11-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング インスリングラルギン／リキシセナチド固定比処方
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
CN115154591B (zh) 2016-12-16 2023-04-14 诺和诺德股份有限公司 含胰岛素的药物组合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2076082A (en) * 1935-04-08 1937-04-06 Nordisk Insulinlab Therapeutic product and process
US2179384A (en) * 1937-04-05 1939-11-07 Univ Alberta Therapeutic composition and process of making it
US2190134A (en) * 1939-06-09 1940-02-13 Norton Co Grinding machine
US2538018A (en) * 1944-04-04 1951-01-16 Nordisk Insulinlab Crystalline product of insulin and alkaline protein and process of making it
US2474729A (en) * 1945-01-03 1949-06-28 Rhone Poulenc Sa Insulin preparations
US2801953A (en) * 1952-02-28 1957-08-06 Hoechst Ag Process of preparing crystallized insulin preparations
US3102077A (en) * 1953-08-19 1963-08-27 Christensen Henry Marinus Preparation of insulin containing 2.75 to 8 percent zinc content
DK98342C (da) * 1959-06-16 1964-03-31 Henry Marinus Dr Christensen Fremgangsmåde til fremstilling af et insulinpræparat til peroral applikation.
US3868358A (en) * 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
GB1426061A (en) * 1972-12-28 1976-02-25 Ici Ltd Polypeptides
US3856771A (en) * 1973-07-16 1974-12-24 Lilly Co Eli Process for manufacturing alkali metal or ammonium insulin
US4196196A (en) * 1978-06-19 1980-04-01 Tiholiz Ivan C Divalen/monovalent bipolar cation therapy for enhancement of tissue perfusion and reperfusion in disease states
AU550068B2 (en) * 1981-03-10 1986-02-27 Novo Nordisk A/S Zinc insulin stabilized with calcium or magnesium salts
US4839341A (en) * 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
US4764592A (en) * 1987-04-23 1988-08-16 Eli Lilly And Company Crystalline human proinsulin and process for its production

Also Published As

Publication number Publication date
AU616381B2 (en) 1991-10-31
EP0265213A2 (en) 1988-04-27
HU201475B (en) 1990-11-28
NO170754B (no) 1992-08-24
NO874347L (no) 1988-04-21
FI86254B (fi) 1992-04-30
CN87107049A (zh) 1988-07-06
GR3004912T3 (sh) 1993-04-28
ES2033871T3 (es) 1993-04-01
AU7990787A (en) 1988-04-21
IE872799L (en) 1988-04-20
CA1316819C (en) 1993-04-27
NZ222214A (en) 1989-11-28
NO874347D0 (no) 1987-10-19
PT85949B (pt) 1990-07-31
IL84203A (en) 1993-04-04
HUT46232A (en) 1988-10-28
EP0265213B1 (en) 1992-04-15
FI874596A0 (fi) 1987-10-19
KR880004819A (ko) 1988-06-27
FI86254C (fi) 1992-08-10
FI874596A (fi) 1988-04-21
YU191887A (en) 1989-04-30
PT85949A (en) 1987-11-01
DE3778287D1 (de) 1992-05-21
PH23446A (en) 1989-08-07
IE60264B1 (en) 1994-06-29
NO170754C (no) 1992-12-02
EP0265213A3 (en) 1988-11-09
US5070186A (en) 1991-12-03

Similar Documents

Publication Publication Date Title
YU46665B (sh) Postupak za dobijanje peptida i novi peptidi
YU46857B (sh) Postupak za dobijanje novih analoga insulina
Tanabe et al. Properties of phosphorylated 32 kd nonamelogenin proteins isolated from porcine secretory enamel
Shapiro Limited proteolysis of some egg surface components is an early event following fertilization of the sea urchin, Strongylocentrotus purpuratus
Joubert et al. Purification, Some Properties and Amino‐Acid Sequences of Two Phospholipases A (CM‐II and CM‐III) from Naja naja kaouthia Venom
SE452250C (sv) Sätt att framställa ett koncentrat av protrombinkomplex
CA1338395C (en) Pharmaceutical containing tissue protein pp4, a process for the pasteurization of pp4, and the use of pp4
Aoba et al. Effects of fluoride on matrix proteins and their properties in rat secretory enamel
US4389343A (en) Immunopotentiating peptides from thymus
Bell α, γ-Diaminobutyric acid in seeds of twelve species of lathyrus and identification of a new natural amino-acid, L-homoarginine, in seeds of other species toxic to man and domestic animals
Thompson et al. Antidotal activity of British anti-lewisite against compounds of antimony, gold and mercury
Lamy et al. Octopus dofleini hemocyanin: structure of the seven-domain polypeptide chain
ATE69727T1 (de) Zusammensetzung zur behandlung von an haemophilia- a-inhibitor leidenden kranken.
Williams et al. Hydrolysis of peptide bonds of the oxidized B-chain of insulin by Endothia parasitica protease
Reiser et al. A high-affinity inositol 1, 3, 4, 5-tetrakisphosphate receptor protein from brain is specifically labelled by a newly synthesized photoaffinity analogue, N-(4-azidosalicyl) aminoethanol (1)-1-phospho-D-myo-inositol 3, 4, 5-trisphosphate
Nomura et al. Structure and action of sperm activating peptides from the egg jelly of a sea urchin, Anthocidaris crassispina
Cohen et al. Synthesis of 5-hydroxypipecolic acid and separation of its diastereoisomers
ATE44750T1 (de) Verfahren zur herstellung eines antihaemophiliefaktor-konzentrats.
US2566123A (en) Stable vitamin b12 solution
US3364116A (en) Method of use of desalanino insulin compositions
Takahashi et al. The amino acid sequence of ribonuclease U1, a guanine-specific ribonuclease from the fungus Ustilago sphaerogena
Punnett et al. Partial purification and some chemical properties of the sperm chemoattractant from the forcipulate starfish Pycnopodia helianthoides (Brandt, 1835)
Hacht et al. Metal ion-FTS nonapeptide interactions. A quantitative study of zinc (II)-nonapeptide complexes (thymulin) under physiological conditions and assessment of their biological significance
Peanasky et al. Inhibitors from Ascaris lumbricoides: interactions with the host’s digestive enzymes
Tsuru et al. Inactivation of Scytalidium lignicolum Acid Protease B with l, 2-Epoxy-3-(4′-azido-2/-nitrophenoxy) propane